B
29.57
0.32 (1.09%)
| Penutupan Terdahulu | 29.25 |
| Buka | 29.73 |
| Jumlah Dagangan | 462,798 |
| Purata Dagangan (3B) | 761,193 |
| Modal Pasaran | 1,301,808,384 |
| Harga / Jualan (P/S) | 9.19 |
| Harga / Buku (P/B) | 2.76 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | -101.62% |
| Margin Operasi (TTM) | -105.69% |
| EPS Cair (TTM) | -1.64 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 36.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.22% |
| Nisbah Semasa (MRQ) | 15.88 |
| Aliran Tunai Operasi (OCF TTM) | -56.10 M |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Beta Bionics, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.51% |
| % Dimiliki oleh Institusi | 98.41% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (Lake Street, 35.27%) | Beli |
| Median | 33.00 (11.60%) | |
| Rendah | 31.00 (Stifel, 4.84%) | Beli |
| Purata | 34.33 (16.10%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 26.52 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Lake Street | 09 Jan 2026 | 40.00 (35.27%) | Beli | 20.14 |
| B of A Securities | 05 Jan 2026 | 33.00 (11.60%) | Beli | 29.57 |
| Truist Securities | 18 Dec 2025 | 37.00 (25.13%) | Beli | 29.06 |
| 29 Oct 2025 | 32.00 (8.22%) | Beli | 26.79 | |
| Goldman Sachs | 29 Oct 2025 | 33.00 (11.60%) | Beli | 26.79 |
| Piper Sandler | 29 Oct 2025 | 32.00 (8.22%) | Beli | 26.79 |
| Stifel | 29 Oct 2025 | 31.00 (4.84%) | Beli | 26.79 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CARNEY SEAN | 17.27 | - | 3,997 | 69,028 |
| DEAREN DANNY L. | 17.27 | - | 3,997 | 69,028 |
| JONES CHRISTY | 17.27 | - | 3,997 | 69,028 |
| LEZACK ADAM | 17.27 | - | 3,997 | 69,028 |
| MICHEL GERARD J | 17.27 | - | 3,997 | 69,028 |
| PALASIS MARIA | 17.27 | - | 3,997 | 69,028 |
| Jumlah Keseluruhan Kuantiti Bersih | 23,982 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 414,169 | |||
| Purata Pembelian Keseluruhan ($) | 17.27 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| DEAREN DANNY L. | Pengarah | 13 Jan 2026 | Diperolehi (+) | 3,997 | 17.27 | 69,028 |
| JONES CHRISTY | Pengarah | 13 Jan 2026 | Diperolehi (+) | 3,997 | 17.27 | 69,028 |
| LEZACK ADAM | Pengarah | 13 Jan 2026 | Diperolehi (+) | 3,997 | 17.27 | 69,028 |
| CARNEY SEAN | Pengarah | 13 Jan 2026 | Diperolehi (+) | 3,997 | 17.27 | 69,028 |
| PALASIS MARIA | Pengarah | 13 Jan 2026 | Diperolehi (+) | 3,997 | 17.27 | 69,028 |
| MICHEL GERARD J | Pengarah | 13 Jan 2026 | Diperolehi (+) | 3,997 | 17.27 | 69,028 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 15 Jan 2026 | Pengumuman | Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 |
| 08 Jan 2026 | Pengumuman | Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics |
| 08 Dec 2025 | Pengumuman | Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026 |
| 03 Nov 2025 | Pengumuman | Beta Bionics Announces Participation at Upcoming Investor Conferences |
| 28 Oct 2025 | Pengumuman | Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |